Date: Monday, June 13, 2016
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Halls C&D
Living kidney donation has significantly improved recipient and graft survival world wide. With a move to increase these numbers further, it becomes mandatory to have a better understanding of the long term outcomes and risks of kidney donation. To investigate the effect of baseline co-morbidity on all-cause mortality in kidney transplant living donors – 10 year follow up. National Health Service and Blood and Transplant, U.K (NHSBT), obtains informed consent from all patients undergoing a transplant in the UK for continuing data collection and subsequent analyses. The study protocol was reviewed and passed by the Renal Registry (RR) projects advisory group, UK. From January 1, 2001 until December 31, 2013 inclusive, all live kidney donors in the U.K were included in the study. No formal sample size estimate was produced for the study; all eligible patients records were used. December 31, 2014 was considered the study end, meaning that all patients had at least one year of follow-up. Datasets, based on regular returns from individual transplant centres across the UK, were obtained from NHSBT. There were 9750 live donor records available. All cause mortality and baseline comorbidity was analysed. 9043 donors had no baseline co morbid condition. The baseline comorbidities analysed were kidney stones (9), microscopic haematuria (9), angina/ischemic heart disease (6), CABG (4), CVA/TIA (5), hypertension (HT) (220), HT on more than 3 medications (1), HT with left ventricular hypertrophy (12). diabetes (2), depression (33), asthma (130), hypercholesterolemia (22) and different BMI bands, BMI <18.5 (82), 18.5 -<25 (3208), 25-<30 (4270), 30-<35 (1449), 35-<40 (158), 40+ (28). There were 48 deaths in total; out of which 2 had baseline HT (2/220), 3 had unspecified comorbidities (3/258) ; and 43 deaths had occurred in the group which had no baseline co-morbidities in the 10 year follow up period. Cox proportional hazards regression modelling, showed no individual baseline comorbidity or "any" combined baseline comorbidity to be a significant predictor of mortality over the follow-up period.There is no significant association between baseline co-morbidities and mortality in living donors in the 10 year follow up study.
CITATION INFORMATION: Krishnan N, Bradbury L, Raymond N. Effect of Baseline Co-Morbidity on Mortality in Living Kidney Donors – 10 Year UK Cohort Study. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:Krishnan N, Bradbury L, Raymond N. Effect of Baseline Co-Morbidity on Mortality in Living Kidney Donors – 10 Year UK Cohort Study. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/effect-of-baseline-co-morbidity-on-mortality-in-living-kidney-donors-10-year-uk-cohort-study/. Accessed September 26, 2020.
« Back to 2016 American Transplant Congress